Literature DB >> 18667695

Death receptor 5 mediated-apoptosis contributes to cholestatic liver disease.

Kazuyoshi Takeda1, Yuko Kojima, Kenichi Ikejima, Kenichi Harada, Shunhei Yamashina, Kyoko Okumura, Tomonori Aoyama, Steffen Frese, Hiroko Ikeda, Nicole M Haynes, Erika Cretney, Hideo Yagita, Noriyoshi Sueyoshi, Nobuhiro Sato, Yasuni Nakanuma, Mark J Smyth, Ko Okumura.   

Abstract

Chronic cholestasis often results in premature death from liver failure with fibrosis; however, the molecular mechanisms contributing to biliary cirrhosis are not demonstrated. In this article, we show that the death signal mediated by TNF-related apoptosis-inducing ligand (TRAIL) receptor 2/death receptor 5 (DR5) may be a key regulator of cholestatic liver injury. Agonistic anti-DR5 monoclonal antibody treatment triggered cholangiocyte apoptosis, and subsequently induced cholangitis and cholestatic liver injury in a mouse strain-specific manner. TRAIL- or DR5-deficient mice were relatively resistant to common bile duct ligation-induced cholestasis, and common bile duct ligation augmented DR5 expression on cholangiocytes, sensitizing mice to DR5-mediated cholangitis. Notably, anti-DR5 monoclonal antibody-induced cholangitis exhibited the typical histological appearance, reminiscent of human primary sclerosing cholangitis. Human cholangiocytes constitutively expressed DR5, and TRAIL expression and apoptosis were significantly elevated in cholangiocytes of human primary sclerosing cholangitis and primary biliary cirrhosis patients. Thus, TRAIL/DR5-mediated apoptosis may substantially contribute to chronic cholestatic disease, particularly primary sclerosing cholangitis.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18667695      PMCID: PMC2504811          DOI: 10.1073/pnas.0802702105

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  43 in total

Review 1.  The TNF and TNF receptor superfamilies: integrating mammalian biology.

Authors:  R M Locksley; N Killeen; M J Lenardo
Journal:  Cell       Date:  2001-02-23       Impact factor: 41.582

Review 2.  Primary sclerosing cholangitis: summary of a workshop.

Authors:  Nicholas F LaRusso; Benjamin L Shneider; Dennis Black; Gregory J Gores; Stephen P James; Edward Doo; Jay H Hoofnagle
Journal:  Hepatology       Date:  2006-09       Impact factor: 17.425

3.  Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosis-inducing ligand.

Authors:  M Jo; T H Kim; D W Seol; J E Esplen; K Dorko; T R Billiar; S C Strom
Journal:  Nat Med       Date:  2000-05       Impact factor: 53.440

4.  Involvement of tumor necrosis factor-related apoptosis-inducing ligand in surveillance of tumor metastasis by liver natural killer cells.

Authors:  K Takeda; Y Hayakawa; M J Smyth; N Kayagaki; N Yamaguchi; S Kakuta; Y Iwakura; H Yagita; K Okumura
Journal:  Nat Med       Date:  2001-01       Impact factor: 53.440

5.  Innate immune response to double-stranded RNA in biliary epithelial cells is associated with the pathogenesis of biliary atresia.

Authors:  Kenichi Harada; Yasunori Sato; Keita Itatsu; Kumiko Isse; Hiroko Ikeda; Mitsue Yasoshima; Yoh Zen; Akira Matsui; Yasuni Nakanuma
Journal:  Hepatology       Date:  2007-10       Impact factor: 17.425

6.  Phase 1 and pharmacokinetic study of lexatumumab in patients with advanced cancers.

Authors:  Ruth Plummer; Gerhardt Attard; Simon Pacey; Louise Li; Albiruni Razak; Rebecca Perrett; Mary Barrett; Ian Judson; Stan Kaye; Norma Lynn Fox; Wendy Halpern; Alfred Corey; Hilary Calvert; Johann de Bono
Journal:  Clin Cancer Res       Date:  2007-10-15       Impact factor: 12.531

7.  TRAIL mediates liver injury by the innate immune system in the bile duct-ligated mouse.

Authors:  Alisan Kahraman; Fernando J Barreyro; Steven F Bronk; Nathan W Werneburg; Justin L Mott; Yuko Akazawa; Howard C Masuoka; Charles L Howe; Gregory J Gores
Journal:  Hepatology       Date:  2008-04       Impact factor: 17.425

8.  Phase I pharmacokinetic and biologic correlative study of mapatumumab, a fully human monoclonal antibody with agonist activity to tumor necrosis factor-related apoptosis-inducing ligand receptor-1.

Authors:  Anthony W Tolcher; Monica Mita; Neal J Meropol; Margaret von Mehren; Amita Patnaik; Kristin Padavic; Monique Hill; Theresa Mays; Therese McCoy; Norma Lynn Fox; Wendy Halpern; Alfred Corey; Roger B Cohen
Journal:  J Clin Oncol       Date:  2007-04-10       Impact factor: 44.544

9.  Critical link between TRAIL and CCL20 for the activation of TH2 cells and the expression of allergic airway disease.

Authors:  Markus Weckmann; Adam Collison; Jodie L Simpson; Matthias V Kopp; Peter A B Wark; Mark J Smyth; Hideo Yagita; Klaus I Matthaei; Nicole Hansbro; Bruce Whitehead; Peter G Gibson; Paul S Foster; Joerg Mattes
Journal:  Nat Med       Date:  2007-10-14       Impact factor: 53.440

10.  Increased hepatotoxicity of tumor necrosis factor-related apoptosis-inducing ligand in diseased human liver.

Authors:  Xandra Volkmann; Ute Fischer; Matthias J Bahr; Michael Ott; Frank Lehner; Marion Macfarlane; Gerald M Cohen; Michael P Manns; Klaus Schulze-Osthoff; Heike Bantel
Journal:  Hepatology       Date:  2007-11       Impact factor: 17.425

View more
  58 in total

1.  Death receptor 5 and neuroproliferation.

Authors:  Yanli Niu; Yongqiang Li; Jianfeng Zang; Hongen Huang; Jiexin Deng; Zhanjun Cui; Dongming Yu; Jinbo Deng
Journal:  Cell Mol Neurobiol       Date:  2011-09-22       Impact factor: 5.046

Review 2.  Hepatocyte death: a clear and present danger.

Authors:  Harmeet Malhi; Maria Eugenia Guicciardi; Gregory J Gores
Journal:  Physiol Rev       Date:  2010-07       Impact factor: 37.312

3.  Apoptotic and antitumor activity of death receptor antibodies require inhibitory Fcγ receptor engagement.

Authors:  Fubin Li; Jeffrey V Ravetch
Journal:  Proc Natl Acad Sci U S A       Date:  2012-06-20       Impact factor: 11.205

4.  Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) protein-induced lysosomal translocation of proapoptotic effectors is mediated by phosphofurin acidic cluster sorting protein-2 (PACS-2).

Authors:  Nathan W Werneburg; Steve F Bronk; Maria Eugenia Guicciardi; Laurel Thomas; Jimmy D Dikeakos; Gary Thomas; Gregory J Gores
Journal:  J Biol Chem       Date:  2012-05-29       Impact factor: 5.157

Review 5.  Hedgehog signaling in the liver.

Authors:  Alessia Omenetti; Steve Choi; Gregory Michelotti; Anna Mae Diehl
Journal:  J Hepatol       Date:  2010-10-14       Impact factor: 25.083

6.  Aryl hydrocarbon receptor ligand 2,3,7,8-tetrachlorodibenzo-p-dioxin enhances liver damage in bile duct-ligated mice.

Authors:  Jun Ozeki; Shigeyuki Uno; Michitaka Ogura; Mihwa Choi; Tetsuyo Maeda; Kenichi Sakurai; Sadanori Matsuo; Sadao Amano; Daniel W Nebert; Makoto Makishima
Journal:  Toxicology       Date:  2010-11-21       Impact factor: 4.221

7.  Antitumor activities of agonistic anti-TNFR antibodies require differential FcγRIIB coengagement in vivo.

Authors:  Fubin Li; Jeffrey V Ravetch
Journal:  Proc Natl Acad Sci U S A       Date:  2013-11-11       Impact factor: 11.205

Review 8.  The immunopathology of human biliary cell epithelium.

Authors:  Ya-Hui Chuang; Ruth Y Lan; M Eric Gershwin
Journal:  Semin Immunopathol       Date:  2009-06-17       Impact factor: 9.623

9.  Alveolar epithelial cells in idiopathic pulmonary fibrosis display upregulation of TRAIL, DR4 and DR5 expression with simultaneous preferential over-expression of pro-apoptotic marker p53.

Authors:  Khondoker M Akram; Nicola J Lomas; Nicholas R Forsyth; Monica A Spiteri
Journal:  Int J Clin Exp Pathol       Date:  2014-01-15

10.  Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Receptor Deficiency Promotes the Ductular Reaction, Macrophage Accumulation, and Hepatic Fibrosis in the Abcb4-/- Mouse.

Authors:  Anuradha Krishnan; Tomohiro Katsumi; Maria E Guicciardi; Adiba I Azad; Nazli B Ozturk; Christy E Trussoni; Gregory J Gores
Journal:  Am J Pathol       Date:  2020-03-30       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.